Familial adenomatous polyposis coli (FAP) is an autosomal dominant disorder characterized by the formation of hundreds of colorectal adenomatous polyps in young adults. Virtually all individuals with FAP will develop colorectal cancer if prophylactic colectomy is not performed. Moreover, many patients have upper gastrointestinal adenomas which predispose to duodenal carcinoma. Presently, the only effective therapy for FAP is colectomy and lifelong surveillance of the upper gastrointestinal tract. Our long term goal is to discover effective chemopreventative therapy for patients with FAP, representing a model which may provide basic insights into molecular regulation of the adenoma-carcinoma sequence in ordinary colorectal cancer. Sulindac, a nonsteroidal antiinflammatory prostaglandin inhibitor, has been reported anecdotally to resolve adenomatous polyps in 15 FAP patients. Our hypothesis is that sulindac can decrease growth of colorectal adenomas and the associated epithelial hyperproliferation in FAP patients.
Our specific aims are to: a) Administer sulindac to FAP patients in a randomized, placebo-controlled, double-blinded trial. b) Sequentially determine colorectal polyp number by video endoscopy and polyp volume by computerized image analysis. c) Sequentially assess in adenomas and nonpolypoid colorectal mucosa the activity of ornithine decarboxylase and S-adenosylmethionine decarboxylase (enzymes important in the regulation of the polyamine pathway), and epithelial proliferation index by immunohistochemistry with Ki-67 antibody to proliferating cell nuclear antigen.
| van Hattem, Willem Arnout; Langeveld, Danielle; de Leng, Wendy W J et al. (2011) Histologic variations in juvenile polyp phenotype correlate with genetic defect underlying juvenile polyposis. Am J Surg Pathol 35:530-6 |
| Langeveld, Danielle; van Hattem, W Arnout; de Leng, Wendy W J et al. (2010) SMAD4 immunohistochemistry reflects genetic status in juvenile polyposis syndrome. Clin Cancer Res 16:4126-34 |
| van Hattem, W Arnout; Brosens, Lodewijk A A; Marks, Susan Y et al. (2009) Increased cyclooxygenase-2 expression in juvenile polyposis syndrome. Clin Gastroenterol Hepatol 7:93-7 |
| van Hattem, W A; Brosens, L A A; de Leng, W W J et al. (2008) Large genomic deletions of SMAD4, BMPR1A and PTEN in juvenile polyposis. Gut 57:623-7 |
| Brosens, Lodewijk A A; Keller, Josbert J; Pohjola, Leena et al. (2008) Increased expression of cytoplasmic HuR in familial adenomatous polyposis. Cancer Biol Ther 7:424-7 |
| de Leng, W W J; Jansen, M; Carvalho, R et al. (2007) Genetic defects underlying Peutz-Jeghers syndrome (PJS) and exclusion of the polarity-associated MARK/Par1 gene family as potential PJS candidates. Clin Genet 72:568-73 |
| Brosens, Lodewijk A A; van Hattem, Arnout; Hylind, Linda M et al. (2007) Risk of colorectal cancer in juvenile polyposis. Gut 56:965-7 |
| Cruz-Correa, Marcia; Shoskes, Daniel A; Sanchez, Patricia et al. (2006) Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 4:1035-8 |
| Hisamuddin, Irfan M; Wehbi, Mohammad A; Schmotzer, Brian et al. (2005) Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 14:2366-9 |
| Giardiello, Francis M; Hylind, Linda M; Trimbath, Jill D et al. (2005) Oral contraceptives and polyp regression in familial adenomatous polyposis. Gastroenterology 128:1077-80 |
Showing the most recent 10 out of 40 publications
